ENDRA Life Sciences Inc.
NDRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $39 | $33 | $46 | $46 |
| Gross Profit | -$39 | -$33 | -$46 | -$46 |
| % Margin | – | – | – | – |
| R&D Expenses | $432 | $381 | $529 | $638 |
| G&A Expenses | $893 | $0 | $0 | $0 |
| SG&A Expenses | $939 | $887 | $895 | $3,612 |
| Sales & Mktg Exp. | $45 | $0 | $0 | $0 |
| Other Operating Expenses | -$39 | $0 | $0 | $0 |
| Operating Expenses | $1,331 | $1,268 | $1,424 | $4,250 |
| Operating Income | -$1,371 | -$1,301 | -$1,469 | -$4,297 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$225 | $75 | $433 | $148 |
| Pre-Tax Income | -$1,596 | -$1,226 | -$1,036 | -$4,149 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,596 | -$1,226 | -$1,036 | -$4,149 |
| % Margin | – | – | – | – |
| EPS | -2.1 | -1.71 | -1.86 | -7.73 |
| % Growth | -22.8% | 8.1% | 75.9% | – |
| EPS Diluted | -2.1 | -1.71 | -1.86 | -7.73 |
| Weighted Avg Shares Out | 761 | 717 | 558 | 537 |
| Weighted Avg Shares Out Dil | 761 | 717 | 558 | 537 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $39 | $33 | $46 | $46 |
| EBITDA | -$1,557 | -$1,193 | -$991 | -$4,103 |
| % Margin | – | – | – | – |